Welcome to our dedicated page for Pheton Holdings news (Ticker: PTHL), a resource for investors and traders seeking the latest updates and insights on Pheton Holdings stock.
Pheton Holdings Ltd (PTHL) specializes in advanced brachytherapy solutions, with its FTTPS software enhancing precision in cancer radiation treatment. This page provides investors and healthcare professionals with centralized access to official announcements, product updates, and strategic developments.
Discover timely updates on regulatory milestones, technology enhancements, and clinical partnerships that demonstrate PTHL's leadership in oncology-focused healthcare technology. Our curated news collection helps stakeholders track innovations in treatment planning systems and their impact on radiation therapy practices.
Key content includes software advancements, safety certifications, and collaborations with medical institutions. Bookmark this page for direct access to verified updates about Pheton Holdings' contributions to efficient, patient-centered cancer care solutions.
Pheton Holdings , a healthcare solution provider specializing in brachytherapy treatment planning systems, has successfully closed its initial public offering (IPO). The company offered 2,250,000 Class A ordinary shares at $4.00 per share, raising gross proceeds of $9 million. Pheton's shares began trading on the Nasdaq Capital Market under the symbol 'PTHL' on September 5, 2024.
The underwriters have a 45-day option to purchase up to 337,500 additional shares. Proceeds will fund research and development, technology upgrades, market expansion, and operational improvements. CATHAY SECURITIES, INC. led the underwriting, with Dominari Securities as co-underwriter.
Pheton Holdings (PTHL), a healthcare solution provider specializing in treatment planning systems for brachytherapy, announced the pricing of its initial public offering (IPO). The IPO comprises 2,250,000 Class A ordinary shares priced at $4.00 per share, totaling $9 million in gross proceeds before deductions. Underwriters have a 45-day option to purchase an additional 337,500 shares at the IPO price, minus underwriting discounts. Trading is set to commence on the Nasdaq Capital Market on September 5, 2024, under the ticker symbol 'PTHL'. The IPO is expected to close on September 6, 2024, pending customary closing conditions. CATHAY SECURITIES and Dominari Securities are leading the underwriting process. Legal counsel includes Hunter Taubman Fischer & Li for the company and The Crone Law Group P.C. for the underwriters.
FAQ
What is the current stock price of Pheton Holdings (PTHL)?
What is the market cap of Pheton Holdings (PTHL)?
